Document Type : Original Article


1 Department of Immunology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.

2 Department of Neurology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.

3 Modeling of Noncommunicable Diseases Research Center, Hamadan University of Medical Sciences.

4 Neurophysiology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.


Background: Abnormal humoral and cellular immune responses have been reported in immune-mediated polyneuropathies. CD137, as a costimulatory molecule and a TNF receptor superfamily member, has been demonstrated to have a key role in the pathogenesis of many autoimmune as well as inflammatory disorders.
Objective: To evaluate the transcripts levels of CD137, its ligand (CD137L), and the serum levels of soluble CD137 (sCD137) in patients with immune-mediated polyneuropathy.
Methods: A total of 45 patients and 46 sex and age-matched healthy individuals were enrolled in the study. CD137 and CD137L transcript levels were assessed by the Real-Time PCR, and the serum level of sCD137 was measured using the ELISA technique. The Bayesian regression model was used for statistical analysis at the 0.05 significance level in R 4.1.0 statistical environment.
Results: Transcript levels of the CD137 and CD137L were higher in polyneuropathy patients in comparison with the healthy subjects (P=0.006 for both). Conversely, the mean level of sCD137 was significantly lower in the sera of patients compared to the controls (P<0.001).
Conclusion: Our findings point to the possible role of CD137 and CD137L in immune-mediated polyneuropathy pathogenesis. More investigations are required to clarify the exact contributions of the mentioned molecules to the pathogenesis of immune-mediated polyneuropathies.


  1. Kieseier BC, Mathey EK, Sommer C, Hartung HP. Immune-mediated neuropathies. Nature reviews Disease primers. 2018;4(1):31.
  2. Dimachkie MM, Barohn RJ. Guillain-Barré syndrome and variants. Neurol Clin. 2013;31(2):491-510.
  3. Li S, Jin T, Zhang H-L, Yu H, Meng F, Concha Quezada H, et al. Circulating Th17, Th22, and Th1 Cells Are Elevated in the Guillain-Barré Syndrome and Downregulated by IVIg Treatments. Mediators of inflammation. 2014;2014:740947.
  4. Leonhard SE, Mandarakas MR, Gondim FAA, Bateman K, Ferreira MLB, Cornblath DR, et al. Diagnosis and management of Guillain–Barré syndrome in ten steps. Nature Reviews Neurology. 2019;15(11):671-83.
  5. van Doorn PA. Treatment of Guillain-Barré syndrome and CIDP. Journal of the peripheral nervous system : JPNS. 2005;10(2):113-27.
  6. Jung HW, Choi SW, Choi JI, Kwon BS. Serum concentrations of soluble 4-1BB and 4-1BB ligand correlated with the disease severity in rheumatoid arthritis. Exp Mol Med. 2004;36(1):13-22.
  7. Itoh A, Ortiz L, Kachapati K, Wu Y, Adams D, Bednar K, et al. Soluble CD137 Ameliorates Acute Type 1 Diabetes by Inducing T Cell Anergy. Frontiers in Immunology. 2019;10.
  8. Ye L, Jia K, Wang L, Li W, Chen B, Liu Y, et al. CD137, an attractive candidate for the immunotherapy of lung cancer. Cancer science. 2020;111(5):1461-7.
  9. Luu K, Shao Z, Schwarz H. The relevance of soluble CD137 in the regulation of immune responses and for immunotherapeutic intervention. J Leukoc Biol. 2020;107(5):731-8.
  10. Liu S, Dong C, Ubogu EE. Immunotherapy of Guillain-Barré syndrome. Human vaccines & immunotherapeutics. 2018;14(11):2568-79.
  11. Grimmig T, Gasser M, Moench R, Zhu LJ, Nawalaniec K, Callies S, et al. Expression of Tumor-mediated CD137 ligand in human colon cancer indicates dual signaling effects. Oncoimmunology. 2019;8(12):e1651622.
  12. Ajami M, Nazari M, Mahmoodzadeh H, Moazzeni SM. Recombinant CD137‐Fc, its synthesis, and applications for improving the immune system functions, such as tumor immunotherapy and to reduce the inflammation due to the novel coronavirus. Journal of Cellular Biochemistry. 2021;122.
  13. Kiefer R, Dangond F, Mueller M, Toyka KV, Hafler DA, Hartung HP. Enhanced B7 costimulatory molecule expression in inflammatory human sural nerve biopsies. Journal of neurology, neurosurgery, and psychiatry. 2000;69(3):362-8.
  14. Hu W, Janke A, Ortler S, Hartung HP, Leder C, Kieseier BC, et al. Expression of CD28-related costimulatory molecule and its ligand in inflammatory neuropathies. Neurology. 2007;68(4):277-82.
  15. Zhang X, Voskens CJ, Sallin M, Maniar A, Montes CL, Zhang Y, et al. CD137 Promotes Proliferation and Survival of Human B Cells. The Journal of Immunology. 2010;184(2):787.
  16. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology. 1991;41(5):617.
  17. Van der Meché FG, Van Doorn PA, Meulstee J, Jennekens FG. Diagnostic and classification criteria for the Guillain-Barré syndrome. Eur Neurol. 2001;45(3):133-9.
  18. Liu G-z, Gomes AC, Putheti P, Karrenbauer V, Kostulas K, Press R, et al. Increased Soluble 4-1BB Ligand (4-1BBL) Levels in Peripheral Blood of Patients with Multiple Sclerosis. Scandinavian Journal of Immunology. 2006;64(4):412-9.
  19. Lushnikova A, Bohr J, Wickbom A, Münch A, Sjöberg K, Hultgren O, et al. Patients With Microscopic Colitis Have Altered Levels of Inhibitory and Stimulatory Biomarkers in Colon Biopsies and Sera Compared to Non-inflamed Controls. Frontiers in medicine. 2021;8:727412.
  20. Jafarinia M, Ashja-Arvan M, Hosseininasab F, Vakili S, Sadeghi E, Etemadifar M, et al. Evaluation of plasma soluble CD137 level in relapsing-remitting multiple sclerosis patients in comparison with healthy controls in Isfahan Province, Iran. Neurology Asia. 2020;25:361-5.
  21. Yoshimori M, Imadome K-I, Komatsu H, Wang L, Saitoh Y, Yamaoka S, et al. CD137 Expression Is Induced by Epstein-Barr Virus Infection through LMP1 in T or NK Cells and Mediates Survival Promoting Signals. PLOS ONE. 2014;9(11):e112564.
  22. Grose C, Feorino P. EPSTEIN-BARR VIRUS AND GUILLAIN-BARRE SYNDROME. The Lancet. 1972;300(7790):1285-7.
  23. Tam CC, O'Brien SJ, Petersen I, Islam A, Hayward A, Rodrigues LC. Guillain-Barré Syndrome and Preceding Infection with Campylobacter, Influenza and Epstein-Barr Virus in the General Practice Research Database. PLOS ONE. 2007;2(4):e344.
  24. Umapathi T, Lim CS, Ooi EE, Zhang SL, Goh EJ, Tan HC, et al. Asymptomatic dengue infection may trigger Guillain-Barré syndrome. Journal of the peripheral nervous system : JPNS. 2016;21(4):375-7.
  25. Mokhashi N, Narla G, Marchionni C. Guillain-Barre Syndrome in a Patient With Asymptomatic Coronavirus Disease 2019 Infection and Major Depressive Disorder. Cureus. 2021;13(3):e14161. 10.7759/cureus.14161
  26. Chi L, Xu W, Zhang Z, Huang H, Zhang L, Zhou J. Distribution of Th17 cells and Th1 cells in peripheral blood and cerebrospinal fluid in chronic inflammatory demyelinating polyradiculoneuropathy. Journal of the peripheral nervous system : JPNS. 2010;15:345-56.
  27. Dharmadhikari B, Wu M, Abdullah NS, Rajendran S, Ishak ND, Nickles E, et al. CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses. Oncoimmunology. 2016;5(4):e1113367.
  28. Wong HY, Schwarz H. CD137 / CD137 ligand signalling regulates the immune balance: A potential target for novel immunotherapy of autoimmune diseases. J Autoimmun. 2020;112:102499.
  29. Martínez Gómez JM, Croxford JL, Yeo KP, Angeli V, Schwarz H, Gasser S. Development of experimental autoimmune encephalomyelitis critically depends on CD137 ligand signaling. J Neurosci. 2012;32(50):18246-52.
  30. Stoll A, Bruns H, Fuchs M, Völkl S, Nimmerjahn F, Kunz M, et al. CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity. Leukemia. 2021;35(12):3482-96.
  31. Shen D, Chu F, Lang Y, Geng Y, Zheng X, Zhu J, et al. Beneficial or Harmful Role of Macrophages in Guillain-Barré Syndrome and Experimental Autoimmune Neuritis. Mediators of inflammation. 2018;2018:4286364.
  32. Maerten P, Geboes K, De Hertogh G, Shen C, Cadot P, Bullens DMA, et al. Functional expression of 4-1BB (CD137) in the inflammatory tissue in Crohn's disease. Clinical immunology. 2004;112 3:239-46.